

# Synthesis of 6-Aryloxy- and 6-Arylalkoxy-2-chloropurines and Their Interactions with Purine Nucleoside Phosphorylase from *Escherichia coli*

Agnieszka Bzowska<sup>a,\*</sup>, Lucyna Magnowska<sup>a</sup> and Zygmunt Kazimierczuk<sup>b</sup>

<sup>a</sup> Department of Biophysics, Institute of Experimental Physics, University of Warsaw, Żwirki i Wigury 93, 02 089 Warsaw, Poland.

Fax: +(48 22) 822 02 48. E-mail: abzowska@asp.biogeo.uw.edu.pl

<sup>b</sup> Institute of Chemistry, Agricultural University, Rakowiecka 26/30, 02 528 Warsaw, Poland

*Dedicated to Professor Frank Seela on the occasion of his 60th birthday*

\* Author for correspondence and reprint requests

Z. Naturforsch. **54c**, 1055–1067 (1999); received May 31/August 2, 1999

2-Chloropurines, Purine Nucleoside Phosphorylase, Inhibition, *Escherichia coli*, Phase Transfer Reactions

The phase transfer method was applied to perform the nucleophilic substitution of 2,6-dichloropurines by modified arylalkyl alcohol or phenols. Since under these conditions only the 6-halogen is exchanged, this method gives 2-chloro-6-aryloxy- and 2-chloro-6-arylalkoxy-purines. 2-Chloro-6-benzylthiopurine was synthesized by alkylation of 2-chloro-6-thiopurine with benzyl bromide. The stereoisomers of 2-chloro-6-(1-phenyl-1-ethoxy)purine were obtained from *R*- and *S*-enantiomers of *sec*-phenylethylalcohol and 2,6-dichloropurine.

All derivatives were tested for inhibition with purified hexameric *E. coli* purine nucleoside phosphorylase (PNP). For analogues showing  $IC_{50} < 10 \mu M$ , the type of inhibition and inhibition constants were determined. In all cases the experimental data were best described by the mixed-type inhibition model and the uncompetitive inhibition constant,  $K_{iu}$ , was found to be several-fold lower than the competitive inhibition constant,  $K_{ic}$ . This effect seems to be due to the 6-aryloxy- or 6-arylalkoxy substituent, because a natural PNP substrate adenine, as well as 2-chloroadenine, show mixed type inhibition with almost the same inhibition constants  $K_{iu}$  and  $K_{ic}$ .

The most potent inhibition was observed for 6-benzylthio-2-chloro-, 6-benzoyloxy-2-chloro-, 2-chloro-6-(2-phenyl-1-ethoxy), 2-chloro-6-(3-phenyl-1-propoxy)- and 2-chloro-6-ethoxypurines ( $K_{iu} = 0.4, 0.6, 1.4, 1.4$  and  $2.2 \mu M$ , respectively). The *R*-stereoisomer of 2-chloro-6-(1-phenyl-1-ethoxy)purine has  $K_{iu} = 2.0 \mu M$ , whereas inhibition of its *S* counterpart is rather weak ( $IC_{50} > 12 \mu M$ ). More rigid (e.g. phenoxy-), non-planar (cyclohexyloxy-), or more bulky (2,4,6-trimethylphenoxy-) substituents at position 6 of the purine base gave less potent inhibitors ( $IC_{50} = 26, 56$  and  $>100 \mu M$ , respectively). The derivatives are selective inhibitors of hexameric “high-molecular mass” PNPs because no inhibitory activity *vs.* trimeric *Cellulomonas sp.* PNP was detected.

By establishing the ligand-dependent stabilization pattern of the *E. coli* PNP it was shown that the new derivatives, similarly as the natural purine bases, are able to form a dead-end ternary complex with the enzyme and orthophosphate. It was also shown that the derivatives are substrates in the reverse synthetic direction catalyzed by *E. coli* PNP.